Merger Links

Deep Track Capital and Forbion led a $175m Series B round in Mariana Oncology.

Announced

Completed

Transaction Tags

  • Minority
  • Private
  • Private Equity
  • Completed
  • Friendly
  • Single Bidder
  • United States
  • pioneering oncology treatment
  • Biotechnology
  • Acquisition
  • Venture Capital
  • Cross Border

Synopsis

Deep Track Capital, an investment firm focused exclusively on the life sciences industry, and Forbion, a venture capital firm, led a $175m Series B round in Mariana Oncology, a biotechnology research company focused on pioneering oncology treatment, with participation from Atlas Venture, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital and Eli Lilly & Company. "The support of such a strong syndicate of new and existing investors is a testament to Mariana Oncology’s potential. In just 18 months since our Series A, we’ve leveraged our deep expertise in peptide discovery and radiochemistry to advance a diversified portfolio of novel molecules. The proceeds from this financing support the advancement of our pipeline and the initial development of our lead candidate, MC-339, which we anticipate will enter the clinic in 2024 in small cell lung cancer, supported by our own GMP radiopharmaceutical manufacturing,” said Simon Read, Mariana Oncology Founder and CEO.

Sources

Press Release

Mariana Oncology

Transaction Value

£139m

Consideration Type

Cash

Capital Owned

+ Add

Capital bid for

+ Add

EV/Sales

+ Add

EV/EBITDA

+ Add

Share Price Premium

+ Add
Service Providers (1)Dealmakers
Argot Partners

pr advisors

Argot Partners

MERGERLINKS LIMITED • 15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM • CONTACT@MERGERLINKS.COM

© COPYRIGHT 2023 MERGERLINKS.COM. ALL RIGHTS RESERVED.